{"id":"0f6946ec-1f5c-5d9d-b34b-9337ec301a46","stable_key":"ff370329-68a3-573d-96ee-597de78a3967:api-fgr-binding","predicate":"reported_relationship","statement":"Apigenin bound immobilized recombinant human FGR in a concentration-dependent surface-plasmon-resonance assay.","claim_class":"mechanistic","status":"source_recorded","evidence_grade":"ungraded","direction":"neutral","is_public":true,"mechanism_event_id":"267d5567-f0fe-5157-9a85-0dcd29c10015","mechanism_event_label":"Apigenin bound immobilized recombinant human FGR in a concentration-dependent surface-plasmon-resonance assay.","subject":{"id":"4425961f-4764-56d3-9887-87e47749379b","slug":"apigenin","display_name":"Apigenin","entity_type_key":"small_molecule"},"object":{"id":"99aac4ea-e5c3-50f3-8a21-0e954d4ba72d","slug":"human-fgr","display_name":"Human tyrosine-protein kinase FGR","entity_type_key":"protein"},"evidence_count":1,"mechanism_event":{"id":"267d5567-f0fe-5157-9a85-0dcd29c10015","stable_key":"ff370329-68a3-573d-96ee-597de78a3967:api-fgr-binding-event","event_type":"biochemical_relationship","label":"Apigenin bound immobilized recombinant human FGR in a concentration-dependent surface-plasmon-resonance assay.","description":"### api-fgr-binding\n\nApigenin bound immobilized recombinant human FGR in a concentration-dependent surface-plasmon-resonance assay.\nDARTS/CETSA in mouse and human macrophage preparations supplied additional association evidence. Docking alone was not treated as binding proof; no unverified numeric KD assigned.\nModel and exposure: Recombinant human FGR, 0.5–80 micromolar apigenin; Figure 5I and Methods.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Aging-induced Alternation in the Gut Microbiota Impairs Host Antibacterial Defense. | 2025 | https://pubmed.ncbi.nlm.nih.gov/39792643/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC11948050/ | https://doi.org/10.1002/advs.202411008 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"4425961f-4764-56d3-9887-87e47749379b","slug":"apigenin","display_name":"Apigenin","entity_type_key":"small_molecule"},"role":"recorded factor","stoichiometry":null,"state_label":"as reported","sequence_order":0,"notes":""},{"entity":{"id":"99aac4ea-e5c3-50f3-8a21-0e954d4ba72d","slug":"human-fgr","display_name":"Human tyrosine-protein kinase FGR","entity_type_key":"protein"},"role":"measured outcome","stoichiometry":null,"state_label":"not_reported","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Recombinant human FGR, 0.5–80 micromolar apigenin; Figure 5I and Methods.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"interpretation_status","value_text":"Recorded from source with stated access limits; ungraded, not independent replication.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Apigenin collection; exact intervention and molecular form govern interpretation.","comparator":null,"unit":null,"notes":"","entity":{"slug":"apigenin","display_name":"Apigenin","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"Apigenin bound immobilized recombinant human FGR in a concentration-dependent surface-plasmon-resonance assay.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Aging-induced Alternation in the Gut Microbiota Impairs Host Antibacterial Defense. | https://pubmed.ncbi.nlm.nih.gov/39792643/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC11948050/ | https://doi.org/10.1002/advs.202411008","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"source_locator","value_text":"Reviewed reference api-fgr-binding; DARTS/CETSA in mouse and human macrophage preparations supplied additional association evidence. Docking alone was not treated as binding proof; no unverified numeric KD assigned.","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"f830dbdb-7ef1-5704-81e9-734e1ab33339","evidence_kind":"source_excerpt","locator":"Lines 392-398","start_line":392,"end_line":398,"excerpt":"### api-fgr-binding\n\nApigenin bound immobilized recombinant human FGR in a concentration-dependent surface-plasmon-resonance assay.\nDARTS/CETSA in mouse and human macrophage preparations supplied additional association evidence. Docking alone was not treated as binding proof; no unverified numeric KD assigned.\nModel and exposure: Recombinant human FGR, 0.5–80 micromolar apigenin; Figure 5I and Methods.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Aging-induced Alternation in the Gut Microbiota Impairs Host Antibacterial Defense. | 2025 | https://pubmed.ncbi.nlm.nih.gov/39792643/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC11948050/ | https://doi.org/10.1002/advs.202411008 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","model_system":"Recombinant human FGR, 0.5–80 micromolar apigenin; Figure 5I and Methods.","directness":"reported_statement","verification_status":"source_recorded","notes":"Original paraphrase in the retained reviewed reference, not a verbatim primary-paper quotation. Access level is explicit.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"54eac90b-add1-5f56-9036-d900307c5697","stable_key":"import-ff370329-68a3-573d-96ee-597de78a3967","title":"Apigenin: detailed mechanisms of action (reviewed 10 October 2026)","document_type":"imported_text","citation_label":"AI-assisted original curation of primary studies; claim-local access and experimental limitations stated. Includes original-draft correction history. No independent replication claimed.","file_path":"","sha256":"ede6e5c6b91d66b66844f2ff667a7f8303d9ac1281f15dc09db703f7de4da942","revision_id":"b41a39a2-0197-549c-97a5-1765e6696931","review_status":"source_recorded","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}